Form 4: VOLITIONRX CFO Awarded Equity Compensation

VolitionRx's Chief Financial Officer, Terig Hughes, received 26,143 restricted stock units in lieu of cash compensation.

Summary

• Terig Hughes, Chief Financial Officer of VOLITIONRX LTD (VNRX), was awarded 26,143 restricted stock units (RSUs) on August 15, 2025.
• The RSUs were granted under the Issuer's 2015 Stock Incentive Plan and serve as compensation in lieu of cash.
• The RSUs will be earned in six approximately equal monthly installments, commencing on September 1, 2025.
• Vesting will occur in two installments: 13,072 units on November 1, 2025, and 13,071 units on February 1, 2026.
• Vesting is contingent upon the CFO's continued service through each applicable earning and vesting date.
• Upon vesting and settlement, the CFO will receive common stock shares equivalent to the number of earned and vested RSUs.
• Following this transaction, Terig Hughes beneficially owns 533,770 shares of common stock.

Sentiment

Score: 7

Explanation: The RSU award is a positive development as it aligns management's interests with shareholders and conserves cash, which is generally viewed favorably, though it is a routine compensation event.

Positives

• The award of restricted stock units aligns the Chief Financial Officer's interests directly with those of shareholders, incentivizing long-term performance.
• Issuing equity in lieu of cash compensation helps conserve the company's cash reserves.

Negatives

• The Chief Financial Officer is not receiving immediate cash compensation for the portion covered by the RSU award.

Risks

• The vesting of the restricted stock units is subject to the Chief Financial Officer's continued service, meaning the full benefit is not guaranteed if employment ceases before vesting dates.

Future Outlook

The Chief Financial Officer's equity compensation is structured to vest over the next several months, with earning commencing in September 2025 and final vesting by February 2026, contingent on continued service.

Management Comments

• The Chief Financial Officer was awarded 26,143 restricted stock units in lieu of cash compensation.

Industry Context

This Form 4 filing details a routine insider transaction involving executive compensation. The award of restricted stock units is a common practice in the industry to incentivize long-term performance and align management interests with shareholders.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a form of executive compensation is a widely adopted practice across various industries, including biotechnology and healthcare, similar to companies like Exact Sciences Corp. or Guardant Health, Inc., which frequently utilize equity awards to retain and incentivize key personnel.
• Structuring RSU awards with earning and vesting schedules tied to continued service is standard, ensuring executive commitment over a defined period, comparable to compensation structures seen at many publicly traded companies.

Corporate Governance

Related Party Transactions

• The award of restricted stock units to the Chief Financial Officer constitutes a related party transaction, as it involves compensation between the company and a key executive.

Stakeholder Impact

• Shareholders: Interests are further aligned with management through equity compensation, potentially leading to better long-term performance.
• Employees: The use of equity compensation for executives may set a precedent or reflect a broader compensation philosophy within the company.

Next Steps

• The Chief Financial Officer's restricted stock units will begin earning in monthly installments starting September 1, 2025.
• The first vesting of 13,072 RSUs is scheduled for November 1, 2025.
• The second vesting of 13,071 RSUs is scheduled for February 1, 2026.

Key Dates

Recommendation

This filing is a routine Form 4 detailing an executive's equity compensation. It does not provide new information on the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. It primarily indicates standard corporate governance and compensation practices.

Keywords

Form 4, Restricted Stock Units, RSU, Executive Compensation, Insider Transaction, Equity Award, VNRX, VolitionRx, Chief Financial Officer